Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

A Phenome-Wide Association Study Uncovers a Pathological Role of Coagulation Factor X during Acinetobacter baumannii Infection.

Choby JE, Monteith AJ, Himmel LE, Margaritis P, Shirey-Rice JK, Pruijssers A, Jerome RN, Pulley J, Skaar EP.

Infect Immun. 2019 Apr 23;87(5). pii: e00031-19. doi: 10.1128/IAI.00031-19. Print 2019 Mar.

PMID:
30782860
2.

Gene-based FVIIa prophylaxis modulates the spontaneous bleeding phenotype of hemophilia A rats.

Zintner SM, Small JC, Pavani G, Dankner L, Marcos-Contreras OA, Gimotty PA, Kjelgaard-Hansen M, Wiinberg B, Margaritis P.

Blood Adv. 2019 Feb 12;3(3):301-311. doi: 10.1182/bloodadvances.2018027219.

3.

Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse.

Hay CE, Gonzalez GA 3rd, Ewing LE, Reichard EE, Hambuchen MD, Nanaware-Kharade N, Alam S, Bolden CT, Owens SM, Margaritis P, Peterson EC.

PLoS One. 2018 Jun 29;13(6):e0200060. doi: 10.1371/journal.pone.0200060. eCollection 2018.

4.

One amino acid in mouse activated factor VII defines its endothelial protein C receptor (EPCR) binding and modulates its EPCR-dependent hemostatic activity in vivo.

Pavani G, Zintner SM, Ivanciu L, Small JC, Stafford KA, Szeto JH, Margaritis P.

J Thromb Haemost. 2017 Mar;15(3):507-512. doi: 10.1111/jth.13607. Epub 2017 Feb 14.

5.

8(th) Symposium on Hemostasis: Translational and Basic Science Discoveries.

Margaritis P, Key NS.

Thromb Res. 2016 May;141 Suppl 2:S1-3. doi: 10.1016/S0049-3848(16)30352-8.

PMID:
27207413
6.

Sustained correction of FVII deficiency in dogs using AAV-mediated expression of zymogen FVII.

Marcos-Contreras OA, Smith SM, Bellinger DA, Raymer RA, Merricks E, Faella A, Pavani G, Zhou S, Nichols TC, High KA, Margaritis P.

Blood. 2016 Feb 4;127(5):565-71. doi: 10.1182/blood-2015-09-671420. Epub 2015 Dec 23.

7.

Fc-based half-life extension of human FVIIa--a new player for hemophilia treatment?

Margaritis P.

Thromb Res. 2015 May;135(5):775-6. doi: 10.1016/j.thromres.2015.02.030. Epub 2015 Feb 27. No abstract available.

PMID:
25746366
8.

The endothelial protein C receptor enhances hemostasis of FVIIa administration in hemophilic mice in vivo.

Pavani G, Ivanciu L, Faella A, Marcos-Contreras OA, Margaritis P.

Blood. 2014 Aug 14;124(7):1157-65. doi: 10.1182/blood-2014-04-567297. Epub 2014 Jun 23.

9.

An engineered U1 small nuclear RNA rescues splicing defective coagulation F7 gene expression in mice.

Balestra D, Faella A, Margaritis P, Cavallari N, Pagani F, Bernardi F, Arruda VR, Pinotti M.

J Thromb Haemost. 2014 Feb;12(2):177-85. doi: 10.1111/jth.12471.

10.

Does rFVIIa work solo in hemophilia?

Margaritis P.

Blood. 2014 Mar 13;123(11):1631-3. doi: 10.1182/blood-2014-01-551275. No abstract available.

11.

Cellular localization and characterization of cytosolic binding partners for Gla domain-containing proteins PRRG4 and PRRG2.

Yazicioglu MN, Monaldini L, Chu K, Khazi FR, Murphy SL, Huang H, Margaritis P, High KA.

J Biol Chem. 2013 Sep 6;288(36):25908-14. doi: 10.1074/jbc.M113.484683. Epub 2013 Jul 19.

12.

Gene-based continuous expression of FVIIa for the treatment of hemophilia.

Margaritis P.

Front Biosci (Schol Ed). 2012 Jan 1;4:287-99. Review.

PMID:
22202061
13.

ARFI ultrasound monitoring of hemorrhage and hemostasis in vivo in canine von Willebrand disease and hemophilia.

Scola MR, Nichols TC, Zhu H, Caughey MC, Merricks EP, Raymer RA, Margaritis P, High KA, Gallippi CM.

Ultrasound Med Biol. 2011 Dec;37(12):2126-32. doi: 10.1016/j.ultrasmedbio.2011.09.006. Epub 2011 Oct 26.

14.

A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia.

Ivanciu L, Toso R, Margaritis P, Pavani G, Kim H, Schlachterman A, Liu JH, Clerin V, Pittman DD, Rose-Miranda R, Shields KM, Erbe DV, Tobin JF, Arruda VR, Camire RM.

Nat Biotechnol. 2011 Oct 23;29(11):1028-33. doi: 10.1038/nbt.1995.

15.

Mutation in the factor VII hepatocyte nuclear factor 4α-binding site contributes to factor VII deficiency.

Zheng XW, Kudaravalli R, Russell TT, DiMichele DM, Gibb C, Russell JE, Margaritis P, Pollak ES.

Blood Coagul Fibrinolysis. 2011 Oct;22(7):624-7. doi: 10.1097/MBC.0b013e3283497699.

PMID:
21760481
16.

Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo.

Margaritis P, Roy E, Faella A, Downey HD, Ivanciu L, Pavani G, Zhou S, Bunte RM, High KA.

Blood. 2011 Apr 14;117(15):3974-82. doi: 10.1182/blood-2010-09-309732. Epub 2011 Feb 16. Erratum in: Blood. 2012 May 10;119(19):4577.

17.

Gene therapy in haemophilia--going for cure?

Margaritis P, High KA.

Haemophilia. 2010 May;16 Suppl 3:24-8. doi: 10.1111/j.1365-2516.2010.02256.x. Review.

PMID:
20586798
18.

Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B.

Nichols TC, Raymer RA, Franck HW, Merricks EP, Bellinger DA, DeFriess N, Margaritis P, Arruda VR, Kay MA, High KA.

Haemophilia. 2010 May;16 Suppl 3:19-23. doi: 10.1111/j.1365-2516.2010.02255.x. Review.

19.

Long-term expression of canine FVIIa in hemophilic dogs.

Margaritis P.

Thromb Res. 2010 Apr;125 Suppl 1:S60-2. doi: 10.1016/j.thromres.2010.01.040. Epub 2010 Feb 10. Review.

20.

Successful treatment of canine hemophilia by continuous expression of canine FVIIa.

Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA.

Blood. 2009 Apr 16;113(16):3682-9. doi: 10.1182/blood-2008-07-168377. Epub 2008 Dec 23.

21.

Over-expression of factor VIIa in vivo.

Margaritis P.

Thromb Res. 2008;122 Suppl 1:S70-2. doi: 10.1016/S0049-3848(08)70023-9. Review.

PMID:
18691505
22.

Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality.

Aljamali MN, Margaritis P, Schlachterman A, Tai SJ, Roy E, Bunte R, Camire RM, High KA.

J Clin Invest. 2008 May;118(5):1825-34. doi: 10.1172/JCI32878.

23.

A viable mouse model of factor X deficiency provides evidence for maternal transfer of factor X.

Tai SJ, Herzog RW, Margaritis P, Arruda VR, Chu K, Golden JA, Labosky PA, High KA.

J Thromb Haemost. 2008 Feb;6(2):339-45. Epub 2007 Nov 23.

24.

A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin.

Yang C, Feng J, Song W, Wang J, Tsai B, Zhang Y, Scaringe WA, Hill KA, Margaritis P, High KA, Sommer SS.

Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15394-9. Epub 2007 Sep 19.

25.

A novel missense mutation responsible for factor VII deficiency in research Beagle colonies.

Callan MB, Aljamali MN, Margaritis P, Griot-Wenk ME, Pollak ES, Werner P, Giger U, High KA.

J Thromb Haemost. 2006 Dec;4(12):2616-22. Epub 2006 Sep 8.

26.

Advances in gene therapy using factor VIIa in hemophilia.

Margaritis P, High KA.

Semin Hematol. 2006 Jan;43(1 Suppl 1):S101-4. Review.

PMID:
16427374
27.

Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA.

J Clin Invest. 2004 Apr;113(7):1025-31.

28.

Optimized production of high-titer recombinant adeno-associated virus in roller bottles.

Liu YL, Wagner K, Robinson N, Sabatino D, Margaritis P, Xiao W, Herzog RW.

Biotechniques. 2003 Jan;34(1):184-9.

29.

Long-term expression of human clotting factor IX from retrovirally transduced primary human keratinocytes in vivo.

White SJ, Page SM, Margaritis P, Brownlee GG.

Hum Gene Ther. 1998 May 20;9(8):1187-95.

PMID:
9625258

Supplemental Content

Loading ...
Support Center